Last reviewed · How we verify
rhTPO combined with Herombopag + CsA
This combination therapy stimulates platelet production through thrombopoietin receptor agonism while suppressing immune-mediated platelet destruction via immunosuppression.
This combination therapy stimulates platelet production through thrombopoietin receptor agonism while suppressing immune-mediated platelet destruction via immunosuppression. Used for Immune thrombocytopenia (ITP), Aplastic anemia with thrombocytopenia.
At a glance
| Generic name | rhTPO combined with Herombopag + CsA |
|---|---|
| Also known as | experimental |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Thrombopoietin receptor agonist combination with immunosuppressant |
| Target | Thrombopoietin receptor (MPL); calcineurin (CsA target) |
| Modality | Small molecule |
| Therapeutic area | Hematology/Immunology |
| Phase | FDA-approved |
Mechanism of action
Recombinant human thrombopoietin (rhTPO) directly stimulates megakaryopoiesis and platelet production by activating the thrombopoietin receptor. Eltrombopag (Herombopag) is an oral thrombopoietin receptor agonist that further enhances platelet generation. Cyclosporine A (CsA) provides immunosuppressive effects to reduce T-cell mediated destruction of platelets and bone marrow progenitors, addressing the immune component of thrombocytopenia.
Approved indications
- Immune thrombocytopenia (ITP)
- Aplastic anemia with thrombocytopenia
Common side effects
- Headache
- Nausea
- Diarrhea
- Infection (from immunosuppression)
- Renal dysfunction (CsA-related)
- Hypertension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: